Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.1.1.u2
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Product Information [Line Items]    
Total net revenues $ 2,406,391 $ 921
Total operating loss (1,945,230) (1,557,970)
Non-operating income (expense), net (12,913) 36,999
Net loss before income taxes (1,958,143) (1,520,971)
Income tax expense (3,672) (11,819)
Net loss (1,961,815) (1,532,790)
Diagnostic R&D [Member]    
Product Information [Line Items]    
Total net revenues 2,885
Total operating loss (442,599) (389,245)
Laboratory Services [Member]    
Product Information [Line Items]    
Total net revenues [1] 2,403,506 921
Total operating loss (2,736,999) (87)
General Corporate Activities [Member]    
Product Information [Line Items]    
Total operating loss $ (1,172,023) $ (1,169,559)
[1] The majority of the increase versus the prior year is from the acquisition of Precision Pathology Laboratories Services, LLC on September 18, 2024.